UK's ECO Animal Health H1 revenue falls on China weakness

By Reuters News


Overview

  • UK animal health firm's H1 revenue fell to £33 mln from £39 mln on China weakness

  • Adjusted EBITDA for H1 held steady at £3 mln despite lower revenue

  • Company expects FY revenue below consensus but adjusted EBITDA and EPS broadly in line


Outlook

  • Company expects full-year group revenue to fall short of market consensus due to China weakness

  • ECO Animal Health expects adjusted EBITDA and EPS to be broadly in line with consensus

  • Company anticipates improvement in China revenue prospects in H2 as pork prices recover


Result Drivers

  • CHINA REVENUE DECLINE - Co said lower pork prices in China led to reduced spending by producers on animal health products, causing a significant drop in China and Japan segment revenue

  • ASIA GROWTH - Revenue in South and South East Asia grew by more than 50%, offsetting some weakness elsewhere

  • GROSS MARGIN IMPROVEMENT - Co said gross margin improved to about 52% due to continued cost control


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Revenue

GBP 33 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for ECO Animal Health Group PLC is GBp196.00, about 106.3% above its November 5 closing price of GBp95.00

  • The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 27 three months ago


Reuters Recommended Reads

  • Nov 5 - Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall

  • Nov 5 - Zoetis Q3 revenue tops analyst estimates

  • Nov 5 - Rising vet bills drive more Americans to pet insurance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk